MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

University of Liège (ULg), Interface Entreprises-Université, Liege

University of Liège (ULg), Interface Entreprises-Université, Liege
The Interface Entreprises-Université is a multidisciplinary team committed to industry, which is responsible of the Liège University technology transfer (IP protection, licences, spinoff

The company in detail

Profile

The University of Liege is a Community-sponsored university in the French-speaking part of Belgium, which offers a complete range of training at both undergraduate and post-graduate levels. The University comprises eight faculties, among others Medicine, Veterinary Medicine, Sciences and Applied Sciences faculties. The University of Liège counts more than 100 internationally recognized teams in fundamental and applied research in the following fields: pharmaceutical, veterinary and environmental sciences, neurology, biotechnology, microbiology, space and aeronautical research, astronomy with more than 1000 researchers in biotechnology field. Besides its essential missions of teaching and research, the University of Liège play also a role in the economic and cultural development of the Community. Interface Entreprises- Université, responsible of the Liège University technology transfer (IP protection, licencing) is the integration axis tool and its main role is to encourage cross-fertilisation between research units and the world of business and industry. The technology transfer is managed by an affiliated company Gesval which is fully part of Interface Entreprises-Université. The Interface Entreprises-Université is also responsible for the creation of business infrastructure (biotechnology network, water network, space network, Liège Science Park) and University spin-off companies (Eurogentec, Kitozyme, Zentec). Six to eight companies are created each year; half of them are biotechnology companies

Out-licensing

1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
Aerosolized pharmaceutical composition with low potential toxicity, significantly reducing airway inflammation and remodelling More
Anti-inflammatory drugs are commonly spread and used to treat pain, arthrosis, asthma or psoriasis. Our laboratory has developed a new molecule against these diseases with some interesting results. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
Biocompatible and biodegradable nanoparticles designed to encapsulate drug allowing for its absorption and delivery More
AB-Amyloid peptide, Alzheimer, diagnosis, senile plaques, kit More
An immuno-PCR method allowing the detection of proteins, carbohydrates, hormones, bacteria, organic components, aromatic compounds, infections agents,… in complex matrices. More
Benzopyran derivatives, potassium channel activators, relaxant activity on smooth muscle, inhibitors of insulin secretion More
The University of Liege has discovered a new tetrahydroisoquinoline and its derivatives and their preparation exhibiting a significant affinity for SK channels, particularly at the Apamin-sensitive sites of SK channels. More
Synthesis of original drugs with a dual mode of action : thromboxane receptor antagonist and thromboxane synthase inhibitor. These compounds are promising antiplatelet or anti-asthmatic agents. More
Wound healing, VEGF, proteolytic-resistant, angiogenesis More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
Angiogenesis, cancer, diabetic retinopathy, tilted peptide More
Process for depositing a strong adherent polymer coating onto an electrically conductive surface by electrografting. More
A new method for prevention and cure of type 1 diabetes More

Contact details

Valérie Debois
Technology Transfer Advisor

Contact directly

Full contact list

Head office

University of Liège (ULg), Interface Entreprises-Université, Liege
Avenue Pré Aily, 4
Angleur
4031
Belgium

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Labtec Pharma
Need competitive intelligence information
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us